GRI Bio, Inc. (GRI)
NASDAQ: GRI · Real-Time Price · USD
1.380
-0.020 (-1.43%)
At close: Oct 16, 2026, 4:00 PM EDT
1.420
+0.040 (2.90%)
After-hours: Oct 16, 2026, 7:12 PM EDT
GRI Bio Employees
GRI Bio had 4 employees as of December 31, 2025. The number of employees did not change compared to the previous year. That makes GRI Bio the 42,218th largest employer in the world and 6,630th in the United States.
Employees
4
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$2,414,750
Market Cap
3.02M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 4 | 0 | - | 3 | 1 |
| Dec 31, 2024 | 4 | 0 | - | 3 | 1 |
| Dec 31, 2023 | 4 | 3 | 300.00% | 4 | 0 |
| Dec 31, 2022 | 1 | - | - | 1 | 0 |
Related Stocks
| Company Name | Employees |
|---|---|
| HCW Biologics | 35 |
| Aptevo Therapeutics | 33 |
| Calidi Biotherapeutics | 29 |
| Dermata Therapeutics | 9 |
| Ernexa Therapeutics | 7 |
| Eocene | 6 |
| KALA BIO | 6 |
| Mustang Bio | 4 |
GRI News
- 5 days ago - Bristol Phase 3 win underscores opportunity for GRI Bio, says H.C. Wainwright - TheFly
- 20 days ago - GRI Bio to highlight immune modulation, Phase 2a development at IPF Summit - TheFly
- 20 days ago - GRI Bio to Highlight Immune Modulation and Phase 2a Development Insights in IPF at the 10th IPF Summit - GlobeNewsWire
- 20 days ago - GRI Bio Proxy statement: Proxy filing - Filings
- 5 weeks ago - GRI Bio announces new translational biomarker data from GRI-0621-IPF-02 study - TheFly
- 5 weeks ago - GRI Bio Presents New Phase 2a Data at ERS 2026 Defining GRI-0621's Mechanism of Action in IPF Across Nine Mechanistic Pillars - GlobeNewsWire
- 7 weeks ago - GRI Bio Featured in "Why Now" On-Demand Video Webcast - GlobeNewsWire
- 7 weeks ago - GRI Bio to Present Late-Breaking Phase 2a GRI-0621 Data Highlighting Lung Function, Anti-Fibrotic Biomarkers and Favorable Tolerability in IPF at ERS 2026 - GlobeNewsWire